Rationale and design of the African Group a streptococcal infection registry: The AFROStrep study

BMJ Open

Volumn 6, Issue 2, 2016, Pages

  Barth, Dylan D ^a   Engel, Mark E ^a   Whitelaw, Andrew ^b   Alemseged, Abdissa ^c   Sadoh, Wilson E ^d   Ali, Sulafa K M ^e   Sow, Samba O ^f   Dale, James ^g   Mayosi, Bongani M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c JIMMA UNIVERSITY   (Ethiopia)

^d UNIVERSITY OF BENIN   (Nigeria)

^e UNIVERSITY OF KHARTOUM   (Sudan)

^f Centre Pour le Développement des Vaccins CVD Mali   (Mali)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE REGISTRY; DISEASE SURVEILLANCE; GROUP A STREPTOCOCCAL INFECTION; HUMAN; INCIDENCE; LONG TERM CARE; MOLECULAR EPIDEMIOLOGY; MULTICENTER STUDY; PATIENT PARTICIPATION; PREVALENCE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; PUBLIC HEALTH; SORE THROAT; STUDY DESIGN; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; METHODOLOGY; REGISTER; STATISTICS AND NUMERICAL DATA; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

AFRICA; HUMANS; PROSPECTIVE STUDIES; REGISTRIES; RESEARCH DESIGN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 84960371444     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010248     Document Type: Article

References (33)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000;13:470-511.
2. Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-94.
3. Cunningham MW. Streptococcus and rheumatic fever. Curr Opin Rheumatol 2012;24:408-16.
4. Lees EA, Carrol ED. Treating invasive group A streptococcal infections. Paediatr Child Health 2014;24:242-7.
5. Hoge CW, Schwartz B, Talkington DF, et al. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 1993;269:384-9.
6. Lynskey NN, Lawrenson RA, Sriskandan S. New understandings in Streptococcus pyogenes. Curr Opin Infect Dis 2011;24:196-202.
7. Nasser W, Beres SB, Olsen RJ, et al. Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3, 615 genome sequences. Proc Natl Acad Sci USA 2014;111:E1768.76.
8. McDonald M, Brown A, Noonan S, et al. Preventing recurrent rheumatic fever: the role of register based programmes. Heart 2005;91:1131.3.
9. Glicklich R, Dreyer N. Registries for evaluating patient outcomes: a user's guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality, April 2007.
10. [No authors listed]. Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997;46:1.55.
11. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario group A streptococcal study group. N Engl J Med 1996;335:547.54.
12. Public Health England. Group A streptococcal infections: guidance and data. London: Public Health England. https//http://wwwgovuk/government/collections/group-a-streptococcal-infections-guidanceanddata (accessed 27 Apr. 2015).
13. Tyrrell GJ, Lovgren M, Kress B, et al. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J Clin Microbiol 2005;43:1678.83.
14. Martin J, Murchan S, O'Flanagan D, et al. Invasive group A streptococcal disease in Ireland, 2004 to 2010. Euro Surveill 2011;16:pii:19988.
15. Meehan M, Murchan S, Bergin S, et al. Increased incidence of invasive group A streptococcal disease in Ireland, 2012 to 2013. Euro Surveill 2013;18:20556.
16. Lamagni T, Efstratiou A, Dennis J. Increase in invasive group A streptococcal infections in England, Wales and Northern Ireland 2008-2009. Euro Surveillance 2014;14:2008.9.
17. Engel ME, Muhamed B, Whitelaw AC, et al. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage. Pediatr Infect Dis J 2014;33:208.10.
18. Dale JB, Penfound TA, Chiang EY, et al. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011;29:8175.8.
19. Dale JB, Penfound TA, Tamboura B, et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 2013;31:1576.81.
20. Nsubuga P, White ME, Thacker SB, et al. Public health surveillance: a tool for targeting and monitoring interventions. In: Jamison DT, Breman JG, Measham AR, et al., eds. Disease control priorities in developing countries. 2nd edn. Washington DC: World Bank, 2006:997.8.
21. World Health Organisation. The current evidence for the burden of group A streptococcal diseases. WHO Rep. Geneva, Switzerland: WHO, 2005.
22. Hraoui M, Boutiba-Ben Boubaker I, Doloy A, et al. Epidemiological markers of Streptococcus pyogenes strains in Tunisia. Clin Microbiol Infect 2011;17:63.8.
23. Malik EM, Ali SKM. Prediction of bacterial pharyngitis in children using clinical features. Khartoum Med J 2014;07:967.71.
24. Tapia MD, Sow SO, Tamboura B, et al. Streptococcal pharyngitis in schoolchildren in Bamako, Mali. Pediatr Infect Dis J 2015;34:463.8.
25. Tesfaw G, Kibru G, Mekonnen D. Prevalence of group A β-haemolytic Streptococcus among children with pharyngitis in Jimma town, Southwest Ethiopia. Egypt J Ear Nose Throat Allied Sci 2015;16:35.40.
26. Robertson KA, Volmink JA, Mayosi BM. Towards a uniform plan for the control of rheumatic fever and rheumatic heart disease in Africa.the Awareness Surveillance Advocacy Prevention (A. S. A. P.) Programme. S Afr Med J 2006;96(Pt 2):241.
27. Karthikeyan G, Zuhlke L, Engel M, et al. Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. Am Heart J 2012;163:535.40.e1.
28. Olafsdottir LB, Erlendsdottir H, Melo-Cristino J, et al. Invasive infections due to Streptococcus pyogenes: seasonal variation of severity and clinical characteristics, Iceland, 1975 to 2012. Euro Surveill 2014;19:5.14.
29. Altman DG. Statistics and ethics in medical research: III How large a sample? BMJ 1980;281:1336.8.
30. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996;34:953.8.
31. Barth DD, Zuhlke LJ, Joachim A, et al. Effect of distance to health facility on the maintenance of INR therapeutic ranges in rheumatic heart disease patients from Cape Town: no evidence for an association. BMC Health Serv Res 2015;15:219.
32. Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009;9:611.16.
33. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis 2012;25:145.53.